^
12ms
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=27, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Sep 2026 | Trial primary completion date: Nov 2025 --> Sep 2026
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD33 (CD33 Molecule)
|
CD33 positive
|
anti-CD33 CAR T
over1year
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=27, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Aug 2023
Enrollment open • Trial initiation date • CAR T-Cell Therapy
|
CD33 (CD33 Molecule)
|
CD33 positive
|
anti-CD33 CAR T
over1year
Combining Anti-CD33 Chimeric Antigen-Receptor T Cells with the Hypomethylating Agent Decitabine to Treat Acute Myeloid Leukemia (ASGCT 2023)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, causing >10,000 deaths per year in the United States. Moreover, DAC treatment resulted in downregulation of DNA repair pathways, β-Catenin, and Notch signaling pathways.Taken together, we found that the antileukemia activity of CD33 CAR T cells was enhanced by pretreatment of leukemia cells with DAC. This combination represents a clinically relevant therapy for the treatment of patients with r/r AML.
CAR T-Cell Therapy
|
DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule) • CD4 (CD4 Molecule) • DNMT1 (DNA methyltransferase 1) • DNMT3B (DNA Methyltransferase 3 Beta)
|
decitabine • anti-CD33 CAR T
almost2years
New P1 trial • CAR T-Cell Therapy
|
CD33 (CD33 Molecule)
|
CD33 positive
|
anti-CD33 CAR T